Merrimack Pharmaceuticals (MACK) Receiving Somewhat Positive News Coverage, Report Finds
Press coverage about Merrimack Pharmaceuticals (NASDAQ:MACK) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.7907817221983 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Technical Investor Update for Merrimack Pharmaceuticals Inc. (MACK) – Lockport Press (lockportpress.com)
- Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call (finance.yahoo.com)
- Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call – PR Newswire (press release) (prnewswire.com)
- Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121 – Smarter Analyst (smarteranalyst.com)
- Merrimack Pharmaceuticals, Inc. (MACK) Set to Announce Earnings on Tuesday (americanbankingnews.com)
Shares of Merrimack Pharmaceuticals (NASDAQ MACK) traded down $0.01 during mid-day trading on Monday, hitting $11.70. The company’s stock had a trading volume of 102,300 shares, compared to its average volume of 238,527. Merrimack Pharmaceuticals has a one year low of $11.14 and a one year high of $67.90. The company has a current ratio of 2.45, a quick ratio of 2.45 and a debt-to-equity ratio of 0.46.
Merrimack Pharmaceuticals (NASDAQ:MACK) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, missing the consensus estimate of ($1.37) by ($0.81). During the same quarter in the prior year, the firm posted ($4.00) earnings per share. equities analysts expect that Merrimack Pharmaceuticals will post -7.34 EPS for the current year.
A number of research analysts recently issued reports on MACK shares. Robert W. Baird restated a “hold” rating and set a $15.00 price target on shares of Merrimack Pharmaceuticals in a research note on Friday, October 13th. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, ValuEngine upgraded Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a strong buy rating to the company. Merrimack Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $64.53.
WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/06/merrimack-pharmaceuticals-mack-receiving-somewhat-positive-news-coverage-report-finds.html.
In other news, Director Ulrik B. Nielsen sold 21,556 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $14.40, for a total value of $310,406.40. Following the completion of the sale, the director now directly owns 37,437 shares of the company’s stock, valued at approximately $539,092.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ulrik B. Nielsen sold 14,756 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $14.46, for a total value of $213,371.76. Following the completion of the sale, the director now directly owns 37,437 shares of the company’s stock, valued at $541,339.02. The disclosure for this sale can be found here. Insiders sold a total of 44,308 shares of company stock valued at $637,558 over the last three months. Insiders own 8.53% of the company’s stock.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.